July 17 (Bloomberg) -- Generic drugmaker Mylan Inc. won a U.S. federal judge’s order to permanently block business partner GlaxoSmithKline Plc from supplying Apotex Inc. with marketable copies of the antidepressant Paxil CR.
The case dates to 2007, when Glaxo filed a suit accusing Mylan of infringing a Paxil patent, U.S. District Judge Joel Pisano in Trenton, New Jersey, said yesterday in granting an injunction. The parties settled, with Mylan buying a license to sell a generic version of the drug, the judge wrote.
When Glaxo granted a second license to Apotex in 2010, Mylan sued and lost. The U.S. Court of Appeals in Philadelphia reinstated a breach-of-contract claim in July 2013 and sent it back for trial, Pisano wrote.
On March 25, a jury found for Canonsburg, Pennsylvania-based Mylan, and awarded it $106.7 million in damages, finding “Glaxo’s agreement with Apotex breached the license agreement,” Pisano said. Mylan requested the injunction after the trial.
Mary Anne Rhyne, a spokeswoman for London-based Glaxo, didn’t immediately return a call seeking comment on the ruling.
The case is Mylan Inc. v. SmithKline Beecham Corp., 10-cv-04809, U.S. District Court, District of New Jersey (Trenton).
To contact the reporter on this story: Phil Milford in Wilmington, Delaware at firstname.lastname@example.org
To contact the editors responsible for this story: Michael Hytha at email@example.com Andrew Dunn, David Glovin